Auricular Acupressure for Chemotherapy-Induced Nausea and Vomiting in Female Breast Cancer Patients

Breast Neoplasms Clinical Trial

Official title:

The Effects of Auricular Acupressure on Chemotherapy-Induced Nausea and Vomiting in Female Breast Cancer Patients: A Pilot Randomized Controlled Trial

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02403037
• Other study ID #: HSEARS20150213001
• Status: Completed
• Phase: N/A
• First received: March 19, 2015
• Last updated: May 27, 2017
• Start date: July 2015
• Est. completion date: October 2016

Study information

• Verified date: May 2017
• Source: The Hong Kong Polytechnic University
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

To evaluate the feasibility of a three-parallel-arm, placebo-controlled randomized trial using a standard auricular acupressure protocol for managing nausea and vomiting in a homogenous group of female breast cancer patients undergoing chemotherapy.

The null hypotheses of this study are: (1) There will be no significant difference in acute/delayed nausea and vomiting among groups during the intervention period; (2) There will be no significant difference in anticipatory nausea and vomiting among groups before the second cycle of chemotherapy; (3) There will be no significant difference in quality of life status among groups at the end of the first cycle of chemotherapy.

Description:

Chemotherapy-induced nausea and vomiting (CINV) is one of the most common and distressing side-effects among cancer patients undergoing chemotherapy. Despite steady progresses in antiemetic prophylaxis and treatment during the past decades, approximately half of cancer patients receiving moderately to highly emetogenic chemotherapy still experience significant nausea and vomiting. Considering the facts that CINV is difficult to be completely controlled by antiemetics along, healthcare professionals has explored the role of non-pharmacological interventions as adjunctive therapy for controlling CINV. Among which, auricular therapy (AT) is a promising approach but the evidence has still not been concluded.

The aim of this study is to test the feasibility of a randomized controlled trial using auricular acupressure protocol for managing nausea and vomiting in female breast cancer patients undergoing chemotherapy. The objectives of this study will be: (1) to pilot the methodological procedure of the randomized controlled trial using a standard auricular acupressure protocol for controlling CINV; (2) to determine the recruitment rate and attrition rate during the whole study period; (3) to determine the feasibility of the study questionnaires and auricular acupressure protocol to the study participants; (4) to identify potential adverse events associated with auricular acupressure; (5) to preliminarily examine the effects of auricular acupressure on CINV and QoL in female breast cancer patients receiving chemotherapy; (6) to explore patients' experience in completing the trial and receiving the intervention; and (7) to refine the study protocol for a future multicenter, large-scale randomized controlled trial.

A three-parallel-arm, placebo-controlled randomized pilot study will be adopted. One hundred and fourteen breast cancer patients scheduled to receive the first cycle of chemotherapy will be recruited from three provincial hospitals in Fuzhou, China, and will be randomly assigned to one of the three groups: the true AT group, the sham AT group or the standard care group. Participants in the true AT group will receive standard anti-emetic medications plus a 5-day auricular acupressure at the specific ear acupoints, participants in the sham AT group will receive standard anti-emetic medications plus a 5-day auricular acupressure at the same acupoints as in the true AT group without any acupoint stimulation, while participants in the standard care group will only be provided with the standard anti-emetic medications. The feasibility outcomes will be the recruitment rate and consent rate during the recruitment stage, the attrition rate during the whole study period, feasibility of the study questionnaires and auricular acupressure protocol to the study participants, and AT-related adverse events. The future main study outcomes will also be measured including acuteCINV, delayed CINV, anticipatory CINV, and quality of life. After completing the pilot clinical trial, a nested qualitative interview will be conducted to explore participants' experience in completing the trial and receiving the intervention.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 114
• Est. completion date: October 2016
• Est. primary completion date: September 2016
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Adult female patients aged above 18 years old;

• A diagnosis of breast cancer stage I-III;

• Chemotherapy- naive;

• Auricular therapy-naive;

• Be able to communicate in Chinese mandarin;

• Have at least completed a primary school education;

• Agree to participate in the study and be willing to give written informed consent;

• Be scheduled to receive the first cycle of chemotherapy with moderately-high to highly emetogenic potentials;

• Be provided with standard antiemetic medications during chemotherapy.

Exclusion Criteria:

• Extremely weak, disabled or immunocompromised cancer patients;

• Be unable to follow the study instructions to do AT intervention or other research procedures;

• Have concurrent radiotherapy or other kinds of antineoplastic therapy;

• Currently take part in clinical studies on anti-emetic medications or other kinds of non-pharmacological interventions to control CINV, or other studies which are believed to produce potential interactions with this AT trial;

• Have other health problems which may affect the symptoms of CINV such as gastrointestinal disease, liver disease, migraine, tinnitus and Ménière's disease, etc.;

• Ear skin problems which are not appropriate for auricular acupressure including ear infections, ear scars and rashes, ear frostbite, and ear abscess, etc.

Related Conditions & MeSH terms

• Breast Neoplasms
• Nausea
• Vomiting

Intervention

Device:
• True auricular acupressure
A 5-day auricular acupressure at the specific ear acupoints using vaccaria seeds.
• Sham auricular acupressure
A 5-day sham auricular acupressure at the same acupoints as in the true auricular acupressure arm using Junci Medulla but no pressure will be applied.

Drug:
• Standard anti-emetic treatment (5-HT3 receptor antagonists and/or Dexamethasone)
5-HT3 receptor antagonists and/or Dexamethasone will be administered to manage chemotherapy-induced nausea and vomiting.

Locations

Country	Name	City	State
China	Fujian Provincial Cancer Hospital	Fuzhou	Fujian
China	The First People's Hospital of Fujian Province	Fuzhou	Fujian
China	The Second People's Hospital of Fujian Province	Fuzhou	Fujian

Sponsors (1)

Lead Sponsor	Collaborator
The Hong Kong Polytechnic University

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Recruitment Rate	Feasibility outcome	Through study completion, an average of 1 year and 4 months
Primary	Consent Rate	Feasibility outcome	Through study completion, an average of 1 year and 4 months
Primary	Attrition Rate	Feasibility outcome	Through study completion, an average of 1 year and 4 months
Primary	Feasibility of the Study Questionnaires and Auricular Acupressure Protocol	Feasibility outcome	Through study completion, an average of 1 year and 4 months
Primary	Potential Adverse Events associated with Auricular Acupressure	Feasibility outcome	During the 5-day intervention period
Secondary	Occurrence of Acute Vomiting	Secondary outcome	The 2nd day of the first chemotherapy cycle
Secondary	Frequency of Acute Vomiting	Secondary outcome	The 2nd day of the first chemotherapy cycle
Secondary	Occurrence of Acute Nausea	Secondary outcome	The 2nd day of the first chemotherapy cycle
Secondary	Severity of Acute Nausea	Secondary outcome	The 2nd day of the first chemotherapy cycle
Secondary	Occurrence of Delayed Vomiting	Secondary outcome	The 6th day of the first chemotherapy cycle
Secondary	Frequency of Delayed Vomiting	Secondary outcome	The 6th day of the first chemotherapy cycle
Secondary	Occurrence of Delayed Nausea	Secondary outcome	The 6th day of the first chemotherapy cycle
Secondary	Severity of Delayed Nausea	Secondary outcome	The 6th day of the first chemotherapy cycle
Secondary	Anticipatory Nausea and Vomiting	The measure is a composite	The 1st day of the second chemotherapy cycle
Secondary	Quality of Life Status	Secondary outcome	The 21st day of the first chemotherapy cycle